新闻通稿

主页/新闻通稿

Oramed Appoints Yadin Rozov to its Board of Directors

NEW YORK, April 4, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Yadin Rozov to its Board of Directors effective April 1, 2022. The Board determined that Mr. [...]

2022-04-04T08:25:00+00:00分类:新闻通稿|标签:|

Oramed’s Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

- 76 Percent of the Physicians Responded They "Definitely Would" or "Probably Would" Prescribe Oramed's Oral Insulin Candidate for Type 2 Diabetes Patients NEW YORK, March 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the [...]

2022-03-29T08:25:00+00:00分类:新闻通稿|标签:|

Oramed to Present at Barclays Global Healthcare Conference

NEW YORK, March 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present a live company overview at the Barclays Global Healthcare Conference, [...]

2022-03-10T08:25:00+00:00分类:新闻通稿|标签:|

Oramed Issues Annual Message to Shareholders

- Oral insulin program continues to advance with topline efficacy data expected in H2 2022 - Significant value creation opportunities through oral COVID-19 vaccine program and partnerships - Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3, [...]

2022-01-12T08:45:00+00:00分类:新闻通稿|标签:|

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars Prospective patient population of approximately 660 million throughout the Association of Southeast Asian Nations NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals [...]

2021-12-29T06:00:00+00:00分类:新闻通稿|标签:|

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

Oravax's oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax's oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. [...]

2021-12-14T08:00:00+00:00分类:新闻通稿|标签:|

Oramed Pharmaceuticals Appoints Chief Legal Officer

NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, [...]

2021-12-08T07:30:00+00:00分类:新闻通稿|标签:|